Company to report trended outcomes to physicians who prescribe therapies for hereditary angioedema
June 11, 2014
BioRx, a national specialty pharmacy provider, announced today that the company has incorporated hereditary angioedema (HAE) into its BioFeedback health outcomes reporting program. With the addition of HAE, BioRx will be expanding the program for the first time beyond its application in immunoglobulin therapy.
“The BioFeedback program for HAE is the first such program in the industry,” said Eric Hill, co-founder of BioRx. “Physicians who prescribe HAE therapies will now be able to see, over time, how pharmaceutical treatments for HAE are impacting their patients’ health and quality of life.”
Hereditary angioedema is a rare, potentially life-threatening genetic condition that causes painful episodes of swelling (edema) in various parts of the body, including the hands, feet, face, and airway. People suffering from HAE have a low level or decreased function of an important protein in their blood, called C1 esterase inhibitor. Edema attacks can occur spontaneously, with or without warning, and the frequency and severity of attacks can wax and wane over time.
In recent years, multiple biological medications have been approved for the treatment of HAE. Since 2009, BioRx has provided pharmacy and in-home nursing support to patients requiring infused or injectable HAE treatments. A majority of patients are trained to self-administer their medications in order to treat their condition preventively or “on demand” as attacks occur.
“HAE is a lifelong, episodic disease,” said Hill. “There’s no cure and so it’s often best managed by the patient at home. That means that prescribing physicians can be left wondering how their patients are doing.”
BioFeedback reports allow prescribing physicians to monitor the effectiveness of prescribe therapies and adjust or alter treatment as necessary. Through the BioFeedback program, BioRx generates reports for physicians, on a quarterly basis, that chart individual patients’ medication usage along with reported edema attacks, treatments, emergency room visits, hospital stays, missed days of work or school, and overall quality of life. Data is collected from routine, monthly telephone monitoring and intermittent quality of life surveys.
In developing the BioFeedback program for HAE, BioRx consulted with physician thought leaders experienced in the treatment of hereditary angioedema. The company continues to develop and expand the uses of its BioFeedback reporting platform. For more information or questions about the program, call 866.44.BIORX (866.442.4679), email firstname.lastname@example.org, or visit www.haefreedom.com.
About Hereditary Angioedema
Hereditary angioedema (HAE) is a rare, potentially fatal genetic disorder characterized by the deficiency or dysfunction of the plasma protein, C1 esterase inhibitor. Clinical characteristics of HAE include painful swelling of the extremities, face, trunk, abdomen and upper airway. HAE attacks can occur anywhere in the body. The most serious attacks grip the airway. Minor trauma or stress may trigger an attack, but swelling often occurs without a known trigger. Episodes involving the intestinal tract cause severe abdominal pain, nausea and vomiting. Before treatment became available, the mortality rate for HAE patients was as high as 30% due to asphyxiation. There are an estimated 11,000 cases in the United States.
Based in Cincinnati, Ohio, BioRx is one of the nation’s fastest growing providers of specialty pharmaceuticals and infusion services, delivering highly customized care for patients with certain rare and chronic diseases. In addition to serving patients with hereditary angioedema, BioRx offers pharmacy, nursing and education services to patients with hemophilia, primary immune deficiencies, autoimmune disorders, and alpha-1 antitrypsin deficiency. The company’s clinical staff reaches patients and physicians in all 50 states. To learn more about BioRx and its products and services, visit www.biorx.com.